189 related articles for article (PubMed ID: 26368297)
1. Antitumor Necrosis Factor-α Therapy Is Associated With Reduced Risk of Thromboembolic Events in Hospitalized Patients With Inflammatory Bowel Disease.
deFonseka AM; Tuskey A; Conaway MR; Behm BW
J Clin Gastroenterol; 2016 Aug; 50(7):578-83. PubMed ID: 26368297
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists.
Shah R; Ho EY; Kramer JR; Richardson P; Sansgiry S; El-Serag HB; Hou JK
Dig Dis Sci; 2018 Jun; 63(6):1551-1557. PubMed ID: 29663266
[TBL] [Abstract][Full Text] [Related]
3. Comparative risk of incident venous thromboembolism in patients with inflammatory bowel disease initiating tumour necrosis factor-α inhibitors or nonbiologic agents: a cohort study.
Desai RJ; Gagne JJ; Lii J; Liu J; Friedman S; Kim SC
CMAJ; 2017 Nov; 189(47):E1438-E1447. PubMed ID: 29180383
[TBL] [Abstract][Full Text] [Related]
4. Increased risk of venous thromboembolic events with corticosteroid vs biologic therapy for inflammatory bowel disease.
Higgins PD; Skup M; Mulani PM; Lin J; Chao J
Clin Gastroenterol Hepatol; 2015 Feb; 13(2):316-21. PubMed ID: 25038374
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease.
Lobatón T; Ferrante M; Rutgeerts P; Ballet V; Van Assche G; Vermeire S
Aliment Pharmacol Ther; 2015 Aug; 42(4):441-51. PubMed ID: 26104047
[TBL] [Abstract][Full Text] [Related]
6. Steroid but not Biological Therapy Elevates the risk of Venous Thromboembolic Events in Inflammatory Bowel Disease: A Meta-Analysis.
Sarlos P; Szemes K; Hegyi P; Garami A; Szabo I; Illes A; Solymar M; Petervari E; Vincze A; Par G; Bajor J; Czimmer J; Huszar O; Varju P; Farkas N
J Crohns Colitis; 2018 Mar; 12(4):489-498. PubMed ID: 29220427
[TBL] [Abstract][Full Text] [Related]
7. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor.
Byun JM; Lee CK; Rhee SY; Kim HJ; Im JP; Park DI; Eun CS; Jung SA; Shin JE; Lee KM; Cheon JH
Scand J Gastroenterol; 2015 Mar; 50(3):312-20. PubMed ID: 25581784
[TBL] [Abstract][Full Text] [Related]
8. Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System.
Deepak P; Stobaugh DJ; Ehrenpreis ED
J Gastrointestin Liver Dis; 2013 Sep; 22(3):269-76. PubMed ID: 24078983
[TBL] [Abstract][Full Text] [Related]
9. Patterns of anti-TNF use and associated treatment outcomes in inflammatory bowel disease patients: results from an analysis of Dutch health insurance claims data.
Bots SJA; Hoekman DR; Benninga MA; Ponsioen CY; D'Haens GR; Löwenberg M
Neth J Med; 2017 Dec; 75(10):432-442. PubMed ID: 29256410
[TBL] [Abstract][Full Text] [Related]
10. Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis.
Targownik LE; Tennakoon A; Leung S; Lix LM; Singh H; Bernstein CN
Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1061-1070.e1. PubMed ID: 28238957
[TBL] [Abstract][Full Text] [Related]
11. Predicting Hospitalization and Outpatient Corticosteroid Use in Inflammatory Bowel Disease Patients Using Machine Learning.
Waljee AK; Lipson R; Wiitala WL; Zhang Y; Liu B; Zhu J; Wallace B; Govani SM; Stidham RW; Hayward R; Higgins PDR
Inflamm Bowel Dis; 2017 Dec; 24(1):45-53. PubMed ID: 29272474
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor Necrosis Factor Alpha Versus Corticosteroids: A 3-fold Difference in the Occurrence of Venous Thromboembolism in Inflammatory Bowel Disease－A Systematic Review and Meta-analysis.
Székely H; Tóth LM; Rancz A; Walter A; Farkas N; Sárközi MD; Váncsa S; Erőss B; Hegyi P; Miheller P
J Crohns Colitis; 2024 May; 18(5):773-783. PubMed ID: 37952112
[TBL] [Abstract][Full Text] [Related]
13. Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment.
Wauters L; Billiet T; Papamichael K; Ballet V; Joniau S; Verschueren P; Silversmit G; Van Assche G; Vermeire S; Ferrante M
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):84-90. PubMed ID: 27603297
[TBL] [Abstract][Full Text] [Related]
14. Preterm birth in women with inflammatory bowel disease - the association with disease activity and drug treatment.
Bröms G; Granath F; Stephansson O; Kieler H
Scand J Gastroenterol; 2016 Dec; 51(12):1462-1469. PubMed ID: 27739352
[TBL] [Abstract][Full Text] [Related]
15. Effect of Inflammatory Bowel Disease-Related Characteristics and Treatment Interventions on Cardiovascular Disease Incidence.
Thapa SD; Hadid H; Schairer J; Imam W; Jafri SM
Am J Med Sci; 2015 Sep; 350(3):175-80. PubMed ID: 26226548
[TBL] [Abstract][Full Text] [Related]
16. Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases.
Ananthakrishnan AN; Cagan A; Cai T; Gainer VS; Shaw SY; Churchill S; Karlson EW; Murphy SN; Kohane I; Liao KP
Aliment Pharmacol Ther; 2015 Jun; 41(11):1141-8. PubMed ID: 25864945
[TBL] [Abstract][Full Text] [Related]
17. Thromboembolism and resistance to activated protein C in patients with inflammatory bowel disease.
Novacek G; Miehsler W; Kapiotis S; Katzenschlager R; Speiser W; Vogelsang H
Am J Gastroenterol; 1999 Mar; 94(3):685-90. PubMed ID: 10086652
[TBL] [Abstract][Full Text] [Related]
18. The risk of venous thromboembolism during and after hospitalisation in patients with inflammatory bowel disease activity.
Chu TPC; Grainge MJ; Card TR
Aliment Pharmacol Ther; 2018 Nov; 48(10):1099-1108. PubMed ID: 30294897
[TBL] [Abstract][Full Text] [Related]
19. Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease.
Rumman A; Candia R; Sam JJ; Croitoru K; Silverberg MS; Steinhart AH; Nguyen GC
Can J Gastroenterol Hepatol; 2017; 2017():7365937. PubMed ID: 28239601
[No Abstract] [Full Text] [Related]
20. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
